Fig. 4
From: YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression
YTHDF1 high expression correlates with a better clinical outcome. a IHC staining, ×200. The negative, weak, moderate and strong expression of YTHDF1 protein expression patterns in lung squamous cell carcinoma (SCC) or lung adenocarcinoma (ADC). b Quantification data for IHC (a). c, d YTHDF1 high expression in NSCLC correlates with better clinical outcome, data generated from IHC staining (c) and network database (d). e Schematic diagram shows the experimental strategy for cisplatin (DDP) treatment in KP and KPY mice. Representative lung tissues after DDP treatment are shown. f Representative H&E and immunostaining for tumors collected from KP and KPY mice after DDP treatment. Scale bars are indicated for each image. Antibodies are: YTHDF1, Ki67, CC3. g Xenograft tumor masses harvested from indicated mice treated by indicated conditions. DDP: 7 mg per kg, once a week for 3 weeks. h, i Representative IHC staining for indicated xenograft tumors after DDP treatment. Scale bar: 50μm. Antibodies are: Ki67 and CC3. (i) is the quantification data for (h). Means ± SEM, *P < 0.05; **P < 0.01; ***P < 0.001; t-test
